A busy few weeks in biotech and pharma. Here are the stories worth your attention.
AstraZeneca’s EMERALD-3 Shows Immunotherapy Benefit in Liver Cancer Before Surgery
AstraZeneca announced positive results from the EMERALD-3 Phase III trial, which evaluated its checkpoint inhibitor combination — Imfinzi (durvalumab) plus Imjudo (tremelimumab) — combined with lenvatinib and transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC) who are eligible for embolization.
The combination met the primary endpoint, showing a statistically significant improvement in progression-free survival versus TACE alone in the 760-patient trial. Overall survival data are still maturing, though there was a trend toward improvement at the interim analysis.
HCC is the most common form of liver cancer and remains difficult to treat in the intermediate stage where patients are not candidates for surgery or transplant but are not yet on systemic therapy alone. TACE (injection of chemotherapy directly into tumor-feeding vessels, combined with blocking blood flow) has been the standard of care for this population for years with no recent improvements. If these results hold and regulatory submissions go forward, this combination could become a new standard.
What this means for you: For oncology researchers and clinicians, EMERALD-3 is one of the more clinically meaningful trial results of the year. The data will be presented at a forthcoming medical meeting with full details. Watch for the progression-free survival curves and the subgroup analyses by disease stage and patient characteristics.
Eli Lilly Gets Approval for Foundayo, an Oral Weight-Loss Pill
The FDA approved Foundayo in early April — Eli Lilly’s oral weight-loss drug, which joins the crowded GLP-1 and dual-incretin space previously dominated by injectable formulations like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound).
The convenience of an oral formulation addresses one of the primary barriers to adoption of these medications in the obesity management space: injection hesitancy and the logistics of a cold-chain drug requiring self-injection. Whether the oral efficacy profile matches the injectable options in head-to-head comparisons at equivalent dosing will be the question that shapes clinical uptake.
For the broader obesity research field, the Foundayo approval continues the regulatory momentum that has shifted obesity from a lifestyle framing to a recognized medical condition with pharmacological treatment options.
CAR-T Expansion Continues: Kite Pharma Approval for Solid Tumors
Kite Pharma’s CAR-T program received regulatory clearance in April, representing a continued expansion of CAR-T therapy beyond the hematological malignancies where it established its efficacy. The oncology research community has been watching whether the lessons from blood cancers — where CAR-T has transformed outcomes in some settings — can be translated to solid tumors, which present fundamentally different challenges for T cell trafficking, tumor microenvironment penetration, and antigen target availability.
This approval, combined with academic and commercial work on next-generation CAR designs, continues to make 2026 a pivotal year for cellular therapy.
What this means for you: For researchers in immunotherapy and cell therapy, the field is moving fast enough that keeping up with approval milestones matters for framing your own work and grant applications. The regulatory agency’s willingness to grant accelerated approvals in this space signals continued appetite for risky but potentially transformative therapies.
$12 Billion in M&A Reshapes the Sector
Merck, Eli Lilly, and Biogen collectively announced acquisitions totaling over $12 billion in April, while the AI-biology partnership wave reached new scale. Insilico Medicine closed a $2.75B deal with Lilly, and Anthropic announced a $400M acquisition of Coefficient Bio.
The M&A activity reflects a pattern that has been building over several quarters: large pharma using acquisitions to fill pipeline gaps rather than building from early-stage discovery. Companies with validated clinical assets are attracting premium valuations even in an environment where public biotech valuations have been compressed. For early-stage researchers building companies or looking at exit trajectories, the appetite for late-preclinical and early-clinical assets with strong mechanistic stories remains real.
The Anthropic-Coefficient Bio deal is worth noting separately. It signals that large AI companies are increasingly looking to own biology capabilities rather than just partner with biotech. Whether that leads to genuinely new therapeutic approaches or faster versions of existing ones is the open question in AI-driven drug discovery right now.
What to Watch in the Coming Weeks
The major oncology meeting season is approaching, with ASCO’s annual meeting coming in late May/early June. Expect full data readouts from several large Phase III trials that have had high-level results reported earlier in the year — EMERALD-3 will almost certainly be on the program. Key data to look for: full PFS curves, OS data, subgroup analyses by patient characteristics, and safety profiles.
In the CAR-T space, updated follow-up data from the first in vivo CAR T cell generation approaches (using mRNA to engineer T cells inside the body rather than extracting and modifying them ex vivo) are expected to present at major immunology meetings this spring.
For background on the cellular therapy advances driving some of these approvals, see In Vivo CAR T Cell Generation: What a New Nature Study Means for Cancer Therapy.